BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31768018)

  • 21. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
    Velu CS; Chaubey A; Phelan JD; Horman SR; Wunderlich M; Guzman ML; Jegga AG; Zeleznik-Le NJ; Chen J; Mulloy JC; Cancelas JA; Jordan CT; Aronow BJ; Marcucci G; Bhat B; Gebelein B; Grimes HL
    J Clin Invest; 2014 Jan; 124(1):222-36. PubMed ID: 24334453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.
    Brumatti G; Salmanidis M; Kok CH; Bilardi RA; Sandow JJ; Silke N; Mason K; Visser J; Jabbour AM; Glaser SP; Okamoto T; Bouillet P; D'Andrea RJ; Ekert PG
    Oncotarget; 2013 Nov; 4(11):1933-47. PubMed ID: 24177192
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Wang W; Li H; Huang M; Wang X; Li W; Qian X; Jing L
    Open Biol; 2022 Oct; 12(10):220172. PubMed ID: 36285442
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
    Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
    Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PAF1c Subunit CDC73 Is Required for Mouse Hematopoietic Stem Cell Maintenance but Displays Leukemia-Specific Gene Regulation.
    Saha N; Ropa J; Chen L; Hu H; Mysliwski M; Friedman A; Maillard I; Muntean AG
    Stem Cell Reports; 2019 May; 12(5):1069-1083. PubMed ID: 31031188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
    Mian YA; Zeleznik-Le NJ
    Leuk Res; 2016 Jul; 46():51-60. PubMed ID: 27123834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo.
    Fischbach NA; Rozenfeld S; Shen W; Fong S; Chrobak D; Ginzinger D; Kogan SC; Radhakrishnan A; Le Beau MM; Largman C; Lawrence HJ
    Blood; 2005 Feb; 105(4):1456-66. PubMed ID: 15522959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
    Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
    Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.
    Calvo KR; Sykes DB; Pasillas MP; Kamps MP
    Oncogene; 2002 Jun; 21(27):4247-56. PubMed ID: 12082612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
    Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
    Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
    Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model.
    Bansal D; Scholl C; Fröhling S; McDowell E; Lee BH; Döhner K; Ernst P; Davidson AJ; Daley GQ; Zon LI; Gilliland DG; Huntly BJ
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16924-9. PubMed ID: 17068127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
    Yoshino S; Yokoyama T; Sunami Y; Takahara T; Nakamura A; Yamazaki Y; Tsutsumi S; Aburatani H; Nakamura T
    Blood; 2021 Jan; 137(1):75-88. PubMed ID: 32730594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
    Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression.
    Ding X; Yang Z; Zhou F; Wang F; Li X; Chen C; Li X; Hu X; Xiang S; Zhang J
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1647-56. PubMed ID: 23660297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.